Optional product analytics
With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Bull: Accelerated expansion in high-margin specialty pharmaceuticals and international distribution drives a structural operating margin expansion to 1.3%+, generating outsized bottom-line compounding.
The market is incorrectly penalizing Cencora for short-term working capital anomalies, masking the highly durable 23% ROIC.
Cencora operates as a dominant player in the US and global pharmaceutical distribution triopoly. Its massive scale provides a significant cost advantage, generating predictable compounding cash flows despite razor-thin margins.
Cencora operates as a dominant player in the US and global pharmaceutical distribution triopoly. Its massive scale provides a significant cost advantage, generating predictable compounding cash flows despite razor-thin margins.
Massive scale as a dominant triopoly member ensures procurement efficiency and low per-unit costs.
Irreplaceable intermediary connecting highly fragmented retail pharmacies with global biopharma manufacturers.
The market is incorrectly penalizing Cencora for short-term working capital anomalies, masking the highly durable 23% ROIC.
Strong Buy based on an extreme dislocation between an enduring oligopoly moat and transient working capital distortions.
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distributes plasma and other blood products, vaccines, and other specialty pharmaceutical products; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; sales force services to manufacturers; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.
A negative working capital spiral combined with sustained operating margin compression below 1.1% would break the capital return algorithm, rendering share repurchases dilutive.
Cost Advantage: Massive scale as a dominant triopoly member ensures procurement efficiency and low per-unit costs.
Network Effect: Irreplaceable intermediary connecting highly fragmented retail pharmacies with global biopharma manufacturers.
Economic profit is supported when reported returns exceed the company cost-of-capital hurdle.
Unavailable
FCF cliff sensitivity is not model-supported in this run; use the discount-rate and terminal-growth grid as the primary valuation pressure test.
If operating margins expand >1.3%, thesis strengthens significantly. If margins drop <1.1%, reassess moat durability and capital return capacity.
If operating margins expand >1.3%, thesis strengthens significantly. If margins drop <1.1%, reassess moat durability and capital return capacity.
If operating margins expand >1.3%, thesis strengthens significantly. If margins drop <1.1%, reassess durability and capital return capacity.
Mature phase; massive free cash flow supports aggressive share buybacks and dividend growth over heavy capacity reinvestment.
Accelerated specialty pharmaceutical approvals and biosimilar penetration drive a higher-margin distribution product mix.
Prolonged generic deflation and regulatory pricing pressure compress overall distribution fee pools.
Mature phase; massive free cash flow supports aggressive share buybacks and dividend growth over heavy capacity reinvestment.
Core holding for mature compounder allocation. Capitalize on market dislocation caused by transient cash flow optical failures.
Exit if operating margins structurally breach 1.1% to the downside or if regulatory frameworks dismantle the wholesale fee structure.
The market is incorrectly penalizing Cencora for short-term working capital anomalies, masking the highly durable 23% ROIC.
The 63.8% upside reflects a deep dislocation between the unshakeable oligopoly economics and current pricing.
Strong Buy. The valuation gap driven by optical cash flow anomalies presents a rare opportunity to acquire an impenetrable oligopoly asset at a severe discount.
Downside case: The market is incorrectly penalizing Cencora for short-term working capital anomalies, masking the highly durable 23% ROIC.
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
Severe government intervention and generic deflation compress distribution fees. Operating margins fall below 1.1%, breaking the capital return algorithm and driving valuation down significantly.
Aggressive legislative action structurally reduces US branded and generic drug pricing, crushing distribution fee economics and compressing margins below 1%.
Manufacturers systematically bypass wholesale networks for specialty and blockbuster treatments, structurally degrading top-line growth and ROIC.
Intense generic price deflation outpaces unit volume growth, eroding gross profit dollars and causing operating leverage to inflect negatively.
The five developments that would weaken our investment case.
Drug distribution runs on razor-thin operating margins where minor fee concessions or price deflation can destroy profitability. A drop below historical baseline margins signals structural pricing erosion across commercial contracts, eliminating operating leverage and depressing free cash generation.
Current:1.2% for the period ended 2025-09-30
Alert ifPersistently drops below 1.1% over two consecutive quarters
While short-term cash flow volatility often stems from working capital timing differences, persistent cash shortfalls impair financial flexibility. Sustained inability to convert net earnings into cash restricts share buybacks, increases borrowing requirements, and reduces capital returns.
Current:2.493 as of the 2026-05-13 analysis date
Alert ifFalls below 1.0x over any four-quarter measurement window
The wholesale pharmaceutical distribution framework depends on massive scale to maintain bargaining leverage and cost efficiencies. Losing a premier health system or retail pharmacy partner would create substantial volume loss, reducing operational throughput and degrading profit margins.
Current:9.3% for the period ended 2025-09-30
Alert ifDecelerates below 3.0% year-over-year over two consecutive quarters
Specialty pharmaceuticals represent the most profitable segment in wholesale drug distribution. If pharmaceutical manufacturers bypass wholesale intermediaries in favor of direct-to-provider shipping, high-margin revenue streams contract, permanently depressing capital returns and diluting the corporate economic moat.
Current:23.1% as of the 2026-05-13 analysis date
Alert ifFalls below 18.0% over any trailing twelve-month period
Mandatory legislative caps on drug pricing or wholesale distribution margins would severely impair gross profitability. Because distribution margins are already slender, regulatory fee restrictions eliminate commercial flexibility, undermining earnings power and forcing structural cost reductions.
Current:3.6% for the period ended 2025-09-30
Alert ifCompresses below 3.0% over any four-quarter measurement window
Each lens answers a different valuation question. Only included lenses set Fair value; floors and diagnostics provide context.
Project SBC-adjusted EPS, discount each year's earnings at cost of equity, then add a Gordon-growth terminal value.
Project EPS through the explicit advantage period, fade growth as competition catches up, and discount the full stream at cost of equity.
Apply a terminal P/E to the dated forward EPS path, then discount that future share value back to the analysis date.
Solve for the growth rate that makes the model value equal the report-date share price.
Accelerated expansion in high-margin specialty pharmaceuticals and international distribution drives a structural operating margin expansion to 1.3%+, generating outsized bottom-line compounding.
Cencora maintains its oligopoly position, sustaining 1.2% operating margins and low single-digit top-line growth. Massive free cash flow funds steady share repurchases, supporting fair value.
If operating margins expand >1.3%, thesis strengthens significantly. If margins drop <1.1%, reassess moat durability and capital return capacity.
Warning level: Persistently drops below 1.1% over two consecutive quarters. Drug distribution runs on razor-thin operating margins where minor fee concessions or price deflation can destroy profitability. A drop below historical baseline margins signals structural pricing erosion across commercial contracts, eliminating operating leverage and depressing free cash generation.
Warning level: Falls below 1.0x over any four-quarter measurement window. While short-term cash flow volatility often stems from working capital timing differences, persistent cash shortfalls impair financial flexibility. Sustained inability to convert net earnings into cash restricts share buybacks, increases borrowing requirements, and reduces capital returns.
Warning level: Decelerates below 3.0% year-over-year over two consecutive quarters. The wholesale pharmaceutical distribution framework depends on massive scale to maintain bargaining leverage and cost efficiencies. Losing a premier health system or retail pharmacy partner would create substantial volume loss, reducing operational throughput and degrading profit margins.
Warning level: Falls below 18.0% over any trailing twelve-month period. Specialty pharmaceuticals represent the most profitable segment in wholesale drug distribution. If pharmaceutical manufacturers bypass wholesale intermediaries in favor of direct-to-provider shipping, high-margin revenue streams contract, permanently depressing capital returns and diluting the corporate economic moat.
Warning level: Compresses below 3.0% over any four-quarter measurement window. Mandatory legislative caps on drug pricing or wholesale distribution margins would severely impair gross profitability. Because distribution margins are already slender, regulatory fee restrictions eliminate commercial flexibility, undermining earnings power and forcing structural cost reductions.
| $262.17B |
| $293.96B |
| $321.33B |
| +10.4% |
| Gross profit | $8.30B | $8.96B | $9.91B | $11.48B | +11.4% |
| Operating income | $2.39B | $2.39B | $2.25B | $2.68B | +3.8% |
| Net income | $1.70B | $1.75B | $1.51B | $1.55B | -2.9% |
| EPS (diluted) | $8.04 | $8.53 | $7.53 | $7.96 | -0.3% |
| EBITDA | $3.10B | $3.37B | $3.37B | $3.75B | +6.5% |
| R&D | — | — | — | — | — |
| SG&A | $4.85B | $5.31B | $5.66B | $6.49B | +10.2% |
Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.
| Revenue | 321,332,819,000 |
|---|---|
| Cost of revenue | 309,854,280,000 |
| Gross profit | 11,478,539,000 |
| Operating expenses | 7,544,917,000 |
| Operating income | 3,933,622,000 |
| Non-operating items and tax | -2,379,453,000 |
| Net income | 1,554,169,000 |
| Total assets | 76,590,112,000 |
|---|---|
| Cash | 4,356,138,000 |
| Current assets | 52,239,073,000 |
| Total liabilities | 74,843,027,000 |
| Current liabilities | 57,820,539,000 |
| Shareholders’ equity | 1,508,019,000 |
Point-in-time financial data used in the 2026-05-13 analysis.
| Period | Revenue | EBITDA | Net income | Operating cash flow | Free cash flow | Capex | Depreciation and amortization | Stock-based compensation | Share repurchases | Dividends paid | Net debt issuance | Investing cash flow | Financing cash flow | Beginning cash | Ending cash | Cash and investments | Total debt | Operating margin | ROIC | WACC | ROIC − WACC spread |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-09-30 | 238.6B | 3.1B | 1.7B | 2.7B | 2.2B | 496.3M | 709.8M | 93.4M | 483.7M | 391.7M | -923.1M | — | — | — | — | 3.4B | 5.7B | 1.2% | — | — | — |
| 2023-09-30 | 262.2B | 3.4B | 1.7B | 3.9B | 3.5B | 458.4M | 980.8M | 124.6M | 1.2B | 398.8M | -623.3M | — | — | — | — | 2.6B | 4.8B | 1.0% | — | 7.1% | — |
| 2024-09-30 | 294B | 3.4B | 1.5B | 3.5B | 3B | 487.2M | 1.1B | 148M | 1.5B | 416.2M | -385.5M | — | — | — | — | 3.1B | 4.4B | 1.1% | — | 6.1% | — |
| 2025-09-30 | 321.3B | 3.7B | 1.6B | 3.9B | 3.2B | 668M | 1.1B | 148M | 435.5M | 437.1M | 3.2B | — | — | — | — | 4.4B | 7.7B | 1.2% | — | 5.7% | — |
COR trades at 13.2x forward earnings against a peer median of 15.2x; EV/EBITDA of 12.1x against a peer median of 13.7x; 6 peers.
| Immediate entry is aggressively warranted. |
| Cardinal Health Inc. |
| 15.2x |
| 0.2x |
| 12.0x |
| — |
| 1.4% |
| HSIC | Henry Schein Inc. | 11.7x | 0.6x | 12.5x | 8.8% | 5.8% |
| LLY | Eli Lilly and Company | 22.4x | 12.2x | 25.4x | 107.5% | 49.4% |
| JNJ | Johnson & Johnson | 17.6x | 5.6x | 16.7x | 26.4% | 27.4% |
